Nilotinib treatment-free remission study in CML patients-ENESTFreedom

• Research type

  Research Study

• Full title

  A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD)status on first line nilotinib treatment.

• IRAS ID

  124353

• Contact name

  Adam Mead

• Contact email

  adam.mead@imm.ox.ac.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2012-004092-40

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• REC name

  London - Brent Research Ethics Committee

• REC reference

  13/LO/0386

• Date of REC Opinion

  8 Apr 2013

• REC opinion

  Favourable Opinion